Lexicon Pharmaceuticals, Inc.
LXRX· Nasdaq
LXRXLexicon Pharmaceuticals, Inc.
Filed Mar 3, 2023 · 10-K · 62 days after period end · 0001062822-23-000007
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $23.37M | $8.73M |
| Net Income | -$30.49M | -$25.61M | -$5.50M | -$51.14M |
| EPS Diluted | — | — |
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
| — |
| -$0.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 3, 2023 · 62 d after period end
